Answers are grounded in this paper and cite their sources.
Our findings suggest that the QIV provides a superior immunogenicity response compared to the TIV in all age groups evaluated, especially when a lineage mismatch occurred. The safety of QIV was considered similar to the TIV, with no serious or systemic solicited or unsolicited adverse events; tough pain at the injection site was greater for QIV. We recommend caution owing to the high risk of bias in the selection process and no protocol registration.
No takes yet. Share an insight, caveat, or question.
Carregaro et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: